Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
- Latest News
- Most Popular
- Spotlight on Market and Fed Exit Plan
- This Week's Top Value Stocks
- Anatomy of Success: National Retail Properties
- RTI: Buy or Sell: Bank of America (BAC)
- The Best ETF to Play Japan's Surge
- Roundtable Top Picks of the Week
- Top-Rated Zacks Rank Sectors
- Double-Down on These Gaming Stocks
- Railroad Industry Stock Outlook - May 2013
- AWS 5/14: Thinking of Life Without QE
- PFP 5/14: This Is Getting Too Easy
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/14/2013
| Company Name | Symbol | %Change |
|---|---|---|
| INTEROIL COR | IOC | 9.57% |
| INFORMATION | III | 9.47% |
| A M R CP | AAMRQ | 6.83% |
| SCIENTIFIC L | SCIL | 5.26% |
| PACER INTL I | PACR | 5.23% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Negative Earnings Surprises
The company is currently riding a streak of four negative earnings surprises, and has missed in six of the last seven quarters. Investors generally want management to have a better handle on handling the expectations of Wall Street.
The misses are small, but they are misses nonetheless. The June 2012 quarter saw a 5.8% miss while the September 2012 quarter missed by 5%. The December 2012 quarter posted a negative earnings surprise of 2.6% and that was followed by the most recent miss of 1.1% for the March 2013 quarter that was posted on April 30.
Expectations on the top line have seen similar trouble, with the company coming in light on the top line in each of the misses by as much as $3M or 3.1% and as little as $1M or 1.7%.
Company Description
Techne makes biotechnology research & diagnostic products and hematology calibrators and controls. The company was founded in 1976 and is headquartered in Minneapolis, Minnesota.
Estimates Slide
Over the last four quarters, TECG has posted a negative earnings surprise in each quarter. This has led to a lowering of expected earnings, a key component investors use to determine a buy from a sell. The Zacks Consensus estimate for 2013 was $3.49 in June 2012, it tailed off follow each earnings report. The estimate is currently at $3.19 after dropping another $0.02 from last month.
The 2014 earnings estimates aren't being spared. They have moved from $3.67 to $3.31 over the same time period. A more dramatic recent reduction saw the estimates move from $3.37 in April to its current level.
F Valuation
The lower estimates and earnings will typically inflate the valuation metrics if the stock is not moving lower as well. That is the case here as TECH is trading at 21x trailing earnings while the industry average is 18.7x. The forward PE of 20.9x is also higher than the 18.3x industry average. The price to book at 3.4x is slightly higher than the 3.2x industry average while price to sales of 8x is well above the 2.6x industry average.
The Chart
The 3 month chart below shows the stock trading off but also rebounding of late. Investors would be wise to show caution and take a hard look at other comparable companies before making any decision on an investment in TECH.
Brian Bolan is a Stock Strategist for Zacks.com. He is the Editor in charge of the Zacks Home Run Investor service, a Buy and Hold service where he recommends the stocks in the portfolio.
Brian is also the editor of Breakout GrowthTrader a trading service that focuses on small cap stocks and also carries a risk limiting strategy.
Follow Brian Bolan on twitter at @BBolan1
Like Brian Bolan on Facebook
Read the full reports :
Snapshot Report on TECH